BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J, Read T, Murphy-beiner A, Baker-jones M, Nutt D, Erritzoe D, Watts R, Carhart-harris R. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. Front Pharmacol 2022;12:788155. [DOI: 10.3389/fphar.2021.788155] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Modlin NL, Miller TM, Rucker JJ, Kirlic N, Lennard-Jones M, Schlosser D, Aaronson ST. Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. J Affect Disord 2023;326:18-25. [PMID: 36707036 DOI: 10.1016/j.jad.2023.01.077] [Reference Citation Analysis]
2 Beckman M, Poulsen S, Doss M, Stenbæk DS. Editorial: The psychotherapeutic framing of psychedelic drug administration. Front Psychol 2023;14. [DOI: 10.3389/fpsyg.2023.1121234] [Reference Citation Analysis]
3 Marguilho M, Figueiredo I, Castro-Rodrigues P. A unified model of ketamine's dissociative and psychedelic properties. J Psychopharmacol 2023;37:14-32. [PMID: 36527355 DOI: 10.1177/02698811221140011] [Reference Citation Analysis]
4 Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, Carhart-Harris RL. Body mass index (BMI) does not predict responses to psilocybin. J Psychopharmacol 2023;37:107-16. [PMID: 36373934 DOI: 10.1177/02698811221131994] [Reference Citation Analysis]
5 Carhart-Harris RL, Chandaria S, Erritzoe DE, Gazzaley A, Girn M, Kettner H, Mediano PAM, Nutt DJ, Rosas FE, Roseman L, Timmermann C, Weiss B, Zeifman RJ, Friston KJ. Canalization and plasticity in psychopathology. Neuropharmacology 2022;226:109398. [PMID: 36584883 DOI: 10.1016/j.neuropharm.2022.109398] [Reference Citation Analysis]
6 Cherniak AD, Gruneau Brulin J, Mikulincer M, Östlind S, Carhart-harris R, Granqvist P. Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal. The International Journal for the Psychology of Religion 2022. [DOI: 10.1080/10508619.2022.2148061] [Reference Citation Analysis]
7 Turkia M. Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT—A retrospective case study. Psychiatry Research Case Reports 2022;1:100029. [DOI: 10.1016/j.psycr.2022.100029] [Reference Citation Analysis]
8 Schipper S, Nigam K, Piechotta V, Ljuslin M, Beaussant Y, Schwarzer G, Boehlke C. Psychedelic/entactogen-assisted therapy for treatment of anxiety, depression and existential distress in adult palliative care. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd015383] [Reference Citation Analysis]
9 Thal SB, Wieberneit M, Sharbanee JM, Skeffington PM, Baker P, Bruno R, Wenge T, Bright SJ. Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy-A systematized review. J Psychopharmacol 2022;:2698811221127954. [PMID: 36263882 DOI: 10.1177/02698811221127954] [Reference Citation Analysis]
10 Gobbi G, Inserra A, Greenway KT, Lifshitz M, Kirmayer LJ. Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice. Transcult Psychiatry 2022;:13634615221119388. [PMID: 36263521 DOI: 10.1177/13634615221119388] [Reference Citation Analysis]
11 Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2022. [PMID: 36001306 DOI: 10.1001/jamapsychiatry.2022.2096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Brennan W, Belser AB. Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Front Psychol 2022;13:866018. [PMID: 35719571 DOI: 10.3389/fpsyg.2022.866018] [Reference Citation Analysis]